-
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment
Tuesday, April 27, 2021 - 9:12am | 276Read More...ObsEva SA (NASDAQ: OBSV) has initiated the observational PRIMROSE 3 study to evaluate long-term bone mineral density (BMD) in subjects who completed at least 20 weeks of linzagolix treatment in Phase 3 PRIMROSE 1 (U.S. only) and PRIMROSE 2 (Europe and E.U.) studies. PRIMROSE 3...
-
ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects
Wednesday, June 4, 2014 - 10:11am | 420Read More...The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) just wrapped up in Chicago, Illinois with meetings and presentations from May 30 to June 3. At this year's 50th Annual Meeting, more than 25,000 cancer specialists gathered to discuss research on the theme of "...
